Literature DB >> 9525828

The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy.

C Y Hsiung1, S W Leung, C J Wang, S K Lo, H C Chen, L M Sun, F M Fang.   

Abstract

PURPOSE: To analyze the prognostic factors of lung cancer with brain metastases (BM) and evaluate the role of cranial irradiation on survival. METHODS AND MATERIALS: From 1987 to 1994, 159 lung cancer patients with CT scan documented BM were reviewed. All of them underwent cranial irradiation (median radiation dose: 30 Gy). Chemotherapy and surgery of BM were performed in 21 and 10 cases, respectively.
RESULTS: Overall median survival was 3.5 months and one year survival rate was 10.69%. Univariate analysis showed that the significant factors were performance status, age, total radiation dose to brain, BM as the first metastasis, neurosurgery, symptoms of urine/stool incontinence, and synchronous BM. Multivariate analysis indicated that (1) performance status (p = 0.0002), (2) total radiation dose (p = 0.0032), (3) BM as the first metastasis (p = 0.0449), (4) neurosurgery (p = 0.0233), (5) symptoms of urine/stool incontinence (p = 0.0002), and (6) the presence of a midline shift on cranial CT scans (p = 0.0063) were significant prognostic factors.
CONCLUSION: The prognosis of BM in lung cancer patients is extremely poor. Radiotherapy appears as an effective means of palliation with 75% overall symptomatic response rate. Higher radiation dose (> or = 30 Gy) and neurosurgery are associated with longer survival. Good performance status, BM as the first metastasis, absence of sphincter dysfunction, and midline shift on CT scans are favorable prognostic predictors. The role of midline shift is very interesting and needs to be explored further.

Entities:  

Mesh:

Year:  1998        PMID: 9525828     DOI: 10.1023/a:1005775029983

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Palliative care for brain metastases of solid tumour types.

Authors:  I Pladdet; E Boven; J Nauta; H M Pinedo
Journal:  Neth J Med       Date:  1989-02       Impact factor: 1.422

2.  Surgical treatment of primary lung cancer and solitary intracranial metastasis.

Authors:  F P Catinella; C F Kittle; L P Faber; F J Milloy; W H Warren; K A Von Roenn
Journal:  Chest       Date:  1989-05       Impact factor: 9.410

3.  Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience.

Authors:  D J Magilligan; C Duvernoy; G Malik; J W Lewis; R Knighton; J I Ausman
Journal:  Ann Thorac Surg       Date:  1986-10       Impact factor: 4.330

Review 4.  The role of radiation therapy in the treatment of brain metastases.

Authors:  L R Coia
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

Review 5.  Surgical treatment of brain metastases of lung cancer: retrospective analysis of 89 cases.

Authors:  H Nakagawa; Y Miyawaki; T Fujita; S Kubo; K Tokiyoshi; K Tsuruzono; K Kodama; M Higashiyama; O Doi; T Hayakawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

6.  Defining the role of radiosurgery in the management of brain metastases.

Authors:  M P Mehta; J M Rozental; A B Levin; T R Mackie; S S Kubsad; M A Gehring; T J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  Surgical treatment of single brain metastases from non-small-cell lung cancer.

Authors:  N Sundaresan; J H Galicich
Journal:  Cancer Invest       Date:  1985       Impact factor: 2.176

8.  Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991.

Authors:  M Wroński; E Arbit; M Burt; J H Galicich
Journal:  J Neurosurg       Date:  1995-10       Impact factor: 5.115

9.  Brain metastases in breast cancer; natural history, prognostic factors and outcome.

Authors:  W Boogerd; V W Vos; A A Hart; G Baris
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

10.  Lung cancer with a single brain metastasis: therapeutic options.

Authors:  A Rizzi; M Tondini; G Rocco; G Rossi; M Robustellini; F Radaelli; C Della Pona
Journal:  Tumori       Date:  1990-12-31
View more
  8 in total

1.  Icotinib combined whole brain radiotherapy for patients with brain metastasis from lung adenocarcinoma harboring epidermal growth factor receptor mutation.

Authors:  Jin-Rui Li; Ye Zhang; Jia-Lian Zheng
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 2.  Surgical management of brain metastases.

Authors:  J S Weinberg; F F Lang; R Sawaya
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

3.  Quick regression of brain metastases from lung adenocarcinoma with epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A case report and literature review.

Authors:  Huaqiong Huang; Shuangli Zhu; Shaobin Wang; Wen Li
Journal:  Mol Clin Oncol       Date:  2016-06-02

4.  Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors.

Authors:  W Jacot; X Quantin; J M Boher; F Andre; L Moreau; M Gainet; A Depierre; E Quoix; T L Chevalier; J L Pujol
Journal:  Br J Cancer       Date:  2001-04-06       Impact factor: 7.640

5.  Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer.

Authors:  Xiao-Hui Ge; Qiang Lin; Xiao-Cang Ren; Yue-E Liu; Xue-Ji Chen; Dong-Ying Wang; Yong-Qiang Wang; Bin Cao; Zhi-Gang Li; Miao-Ling Liu
Journal:  Radiat Oncol       Date:  2013-10-14       Impact factor: 3.481

6.  Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.

Authors:  Masashi Chonan; Norio Narita; Teiji Tominaga
Journal:  BMC Res Notes       Date:  2016-01-02

7.  Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer.

Authors:  Juan Moreno-Rubio; Santiago Ponce; Rosa Álvarez; María Eugenia Olmedo; Sandra Falagan; Xabier Mielgo; Fátima Navarro; Patricia Cruz; Luis Cabezón-Gutiérrez; Carlos Aguado; Gonzalo Colmenarejo; Marta Muñoz-Fernández de Leglaria; Ana Belén Enguita; María Cebollero; Amparo Benito; Isabel Alemany; Carolina Del Castillo; Ricardo Ramos; Ana Ramírez de Molina; Enrique Casado; Maria Sereno
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

8.  Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.

Authors:  Ying Yuan; Chunwen Tan; Modan Li; Hong Shen; Xuefeng Fang; Yinghong Hu; Shenglin Ma
Journal:  World J Surg Oncol       Date:  2012-11-07       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.